期刊文献+

硼替佐米作用不同时间对K562耐药细胞株核因子-κB途径的影响

Effects of different time points of bortezomib on the pathway of NF-KB in drug-resistant K562 cells
原文传递
导出
摘要 目的观察硼替佐米(商品名:万珂,PS-341)对柔红霉素(DNR)诱导的K562耐药细胞株(K562/DNR)核因子-KB(NF-kB)、抑制蛋白KB(IKB)及P-糖蛋白(P-gP)表达的影响,探讨PS-341逆转耐药的分子机制。方法以100txg/mlDNR单用或联合应用4Pμg/LPS-341分别作用于K562/DNR12、24及36h,检测不同时间点各组NF-KB、IKB及P-gP表达情况,同时测定NF-KBp65活性,检测各组细胞凋亡率。结果Westernblot结果显示:与阴性对照组相比,DNR可诱导NF-kB表达上调及活性增强、IKB表达下调、P-gP表达上调;加用PS-341可显著抑制DNR诱导的NF-kB及P.gP表达,使IKB表达增加。加用PS-341后,NF.KB活性12h为(15.3±1.87)%[DNR组为(23.8±2.27)%],24h为(10.2±1.69)%[DNR组为(25.4±1.98)%1,36h为(6.08±-2.53)%[DNR组为(26.9±2.58)%],与相应单用DNR组相比均有明显下降,差异有统计学意义(P值均〈0.05)。DNR与PS-341联用后,细胞凋亡率12h为(35.23±5.15)%[DNR组为(15.56±4.12)%],24h为(40.26±6.89)%[DNR组为(17.25±2.89)%],36h为(43.58±7.69)%[DNR组为(22.47±4.58)%],与DNR组相比,细胞凋亡率均明显增加,差异具有统计学意义(P值均〈0.05)。上述作用呈时间依赖性。结论PS-341可减少K562/DNR细胞NF-KB的活化,降低P-gP表达,逆转细胞耐药,促进细胞凋亡。 Objective To study the effects of bortezomib on the expression of NF-KB, IKB and P-gp of drug-resistant K562 cells induced by daunorubicin (K562/DNR), to explore the molecular mechanism of drug-resistant reverse. Methods The expression of NF-kB, IkB and P-gp in K562/DNR cells were detected when the cells had been treated with 100 μg/ml DNR only or together with 4 p.g/L bortezomib for 12 h, 24 h and 36 h. The apoptosis rates were detected in each group respectively and the activity of NF-kB was detected by ELISA method. Results Compared with the control group, the expressions of NF-kB and P-gp in K562/ DNR could be increased and IKB was decreased after being treated with DNR. When K562/DNR were cultured with bortezomib, the expressions of NF-KB and P-gp induced by DNR were significantly suppressed and IkB was increased. The activity of NF-kB were detected in different time points: (15.3±1.87) % [(23.8±2.27) % in DNR group] at 12 h, (10.2±1.69) % [(25.4±1.98) % in DNR group] at 24 h, (6.08±2.53) % [(26.9± 2.58) % in DNR group] at 36 h. There were a significant differences between DNR group and DNR+PS-341 group. The apoptosis rates were increased in DNR+PS-341 group at different time points than those in DNR group, (35.23±5.15) % [(15.56±4.12) % in DNR group] at 12 h, (40.26±6.89) % [(17.25±2.89) % in DNR group] at 24 h, (43.58±7.69) % [(22.47±4.58) % in DNR group] at 36 h. The effcets showed the character of time-dependent pattern. Conclusion Bortezomib could downregulate the expressions of NF-KB and P-gp in K562/DNR, reverse the drug resistance and up-regulate the apoptotic rates in K562/DNR cells.
出处 《白血病.淋巴瘤》 CAS 2011年第4期195-198,共4页 Journal of Leukemia & Lymphoma
基金 辽宁省教育厅项目(20060985)
关键词 蛋白酶体抑制剂 NF-KB IkB蛋白 P-糖蛋白 耐药 Proteasome inhibitor NF-kB IkB proteins P-glycoprotein Drug-resistant
  • 相关文献

参考文献10

  • 1Lovborg H,Oberg F,Rickardson L,et al.Inhibition of protetsome activity,nuclear factor-kappa B translocation and cell survival by the antialcoholism drug disulfiram.Int J Cancer,2006,118:1577-1580.
  • 2Guzman ML,Neering SJ,Upcharch D,et al.Nuclear factor-kappa B is constitutively activated in primitive human acute myelogenous leukemia cells.Blood,2001,98:2301-2307.
  • 3Richardson PG,Lauboch J,Mitsiads C,et al.Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.Oncology(Williston Park),2010,24:22-29.
  • 4Laubach JP,Mahindra A,Mitsiades CS,et al.The use of novel agents in the treatment of relapsed and refractory multiple myeloma.Leukemia,2009,23:2222-2232.
  • 5Gil L,Styczynski J,Dytfeld D,et al.Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia.Anticance r Res,2007,27:4021-4025.
  • 6McCloskey SM,McMullin MF,Walker B,et al.The therapeutic potential of the proteasome in leukemia.Hematol Oncol,2008,26:73-81.
  • 7Cilloni D,Martinelli G,Messa F,et al.Nuclear factor κ B as a target for new drug development in myeloid malignancies.Haematologica,2007,92:1224-1229.
  • 8Yates LL,Gorecki DC.The unclear factor-kappaB (NF-kappaB):from a versatile transcription factor to a ubiquitous therapeutic target.Acta Biochim Pol,2006,53:651-662.
  • 9Van Waes C.Nuclear factor-kappa B in development,prevention,and therapy of cancer.Clin Cancer Res,2007,13:1076-1082.
  • 10Hu XF,Slater A,Kantharidis P,et al.Altered multidrug resistance phenotype caused by anthracyeline analogues and cytosinearabinoside in myeloid leukemia.Blood,1999,93:4086-4095.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部